Back to News
Market Impact: 0.2
Gilead To Buy PepStar's IBD Investigational Oral IL-23R Inhibitor Program For $1.275 Bln Cash
Source: Nasdaq
M&A & RestructuringHealthcare & Biotech
Gilead Sciences agreed to acquire PepStar Therapeutics’ investigational oral IL-23R inhibitor program, including lead asset HCXT-2001. The announcement provided no financial terms or development timeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
GILD0.45
More News
- Next week brings major risks for the stock market, just as the AI trade keeps faltering
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Oncologists Cheer Melanoma Data
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- Instacart explores potential sale, holds talks with Uber and DoorDash: report